Drug Trial Radar · NCT06647407
Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants
Last checked: Nov 20, 2026Latest source record: Jan 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
750
Planned (sponsor's estimate)
Start
Nov 5, 2024
Primary completion
May 17, 2027
Study completion May 17, 2027
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 56 days, up to 9 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is the first study of Sanofi's Pentavalent Meningococcal ABCYW vaccine clinical development program to be conducted in the pediatric population below 10 years of age. The aim of the study is to assess 2 formulations of the MenPenta vaccine compared to licensed meningococcal vaccines when administered alone in children (Stage 1) or concomitantly with routine pediatric vaccines in toddlers (Stage 2) and infants (Stage 3). Study details include: The study duration per participant will be up to 12 months for children in Stage 1 and toddlers in Stage 2 and 16 to-19 months for infants in Stage 3.
Conditions
- Meningococcal Immunization
- Healthy Volunteers
Interventions
Pentavalent Meningococcal ABCYW vaccineBiological
Pharmaceutical form: Suspension for injection Route of administration: Intramuscular (IM)
MenACYW conjugate vaccineBiological
Pharmaceutical form: Solution for injection in vial Route of administration: Intramuscular (IM)
MenACYW conjugate vaccineBiological
Pharmaceutical form: Powder and solvent for injectable solution in a pre-filled syringe Route of administration: Intramuscular (IM)
Meningococcal group B vaccineBiological
Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
ParacetamolDrug
Pharmaceutical form:Suspension-Route of administration:oral
DTap-HepB-IPV-Hib vaccineBiological
Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
DTap-HepB-IPV-Hib vaccineBiological
Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
DTap-HepB-IPV-Hib vaccineBiological
Pharmaceutical form: Oral solution in tube Route of administration: oral
Rotavirus vaccineBiological
Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
Pneumococcal 13-valent conjugate vaccineBiological
Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with unsolicited immediate adverse events (AEs)Time frame: Within 30 minutes after each vaccination
- Number of participants with solicited injection site reactions or systemic reactionsTime frame: Within 7 days after each vaccination
- Number of participants with unsolicited AEsTime frame: Within 30 days after each vaccination
- Number of participants with serious adverse events (SAEs)Time frame: Throughout the study, from first visit until 180 days after the last vaccination
- hSBA meningococcal serogroups A, C, W, and Y antibody titers pre-dose and 30 days after the second and third dose in infant participantsTime frame: For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391
- hSBA meningococcal serogroups A, C, W, and Y vaccine seroresponse pre-dose and 1 month after the second and third dose in infant participantsTime frame: For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391
- Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroups A, C, W and Y pre-dose and 1 month after the second and third dose in infant participantsTime frame: For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391
- Percentage of participants with hSBA titers more or equal to lower limit of quantification (LLOQ) against each of serogroups A, C, W, and Y pre-dose and 1 month after the second and third dose in infant participantsTime frame: For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391
- Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:4 pre-dose and 1 month after second dose of vaccination against serogroup B, before and 30 days after third dose in infantsTime frame: For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391
- Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:8 pre-dose and 1 month after the second dose of vaccination against serogroup B, before and 30 days after third dose in infantsTime frame: For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391
- hSBA meningococcal serogroup B seroresponse pre-dose and 1 month after the second dose of vaccination against serogroup B, before and 30 days after third dose in infant participantsTime frame: For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391
- Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroup B (reference MenB strains) pre-dose and 1 month after the second dose of vaccination against serogroup B, before and 30 days after third dose in infant participantsTime frame: Day 01, Day 91, Day 181 and Day 211 (for Stage 3)
- Percentage of participants with hSBA titers more or equal to lower limit of quantification (LLOQ) against each and all of serogroup B (ref. MenB strains) predose and 1 month after 2nd dose against serogroup B, before and 30 days after 3rd dose in infantsTime frame: For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391
- Percentage of participants with hSBA titers less than LLOQ against all serogroup B (ref. MenB strains) pre-dose and 1 month after the 2nd dose of vaccination against serogroup B, before and 30 days after 3rd dose in infantsTime frame: For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391
- hSBA meningococcal serogroups A, C, W, and Y antibody titers in children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211
- hSBA meningococcal serogroups A, C, W, and Y vaccine seroresponse in children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211
- Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroups A, C, W and Y pre-dose and 1 month after the second dose children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211
- Percentage of participants with hSBA titers more or equal to lower limit of quantification (LLOQ) against each of serogroups A, C, W, and Y children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211
- Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:4 in children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211
- Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:8 in children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211
- hSBA meningococcal serogroup B (reference MenB strains) vaccine seroresponse in children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211
- Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroup B (reference MenB strains) in children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211
- Percentage of participants with hSBA titers more or equal to lower limit of quantification (LLOQ) against each and all of serogroup B (reference MenB strains) in children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211
- Percentage of participants with hSBA titers less than the lower limit of quantification (LLOQ) against all serogroup B (reference MenB strains) in children and toddlersTime frame: For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211
Locations
39 sites in 9 countries. Site status is shown where the registry gives one.
Hospital das Clínicas da Universidade Federal de Minas Gerais- Site Number : 0760001
Belo Horizonte, Minas Gerais, Brazil
Private Practice - Dr. Nelson Rosário- Site Number : 0760004
Curitiba, Paraná, Brazil
Investigational Site Number : 2030003
Jindřichův Hradec, Czechia
Investigational Site Number : 2030004
Ostrava, Czechia
Investigational Site Number : 2030007
Pilsen, Czechia
Investigational Site Number : 2030008
Prague, Czechia
Investigational Site Number : 2030009
Prague, Czechia
Investigational Site Number : 2080002
Hvidovre, Denmark
Investigational Site Number : 2080003
Odense, Denmark
Investigational Site Number : 2460006
Espoo, Finland
Investigational Site Number : 2460001
Helsinki, Finland
Investigational Site Number : 2460008
Helsinki, Finland
Investigational Site Number : 2460005
Jarvenpaa, Finland
Investigational Site Number : 2460004
Oulu, Finland
Investigational Site Number : 2460002
Seinäjoki, Finland
Investigational Site Number : 2460007
Tampere, Finland
Investigational Site Number : 2760008
Herxheim, Germany
Investigational Site Number : 2760006
Hürth, Germany
Investigational Site Number : 2760007
Hürth, Germany
Investigational Site Number : 2760005
Krefeld, Germany
Investigational Site Number : 2760009
Mönchengladbach, Germany
Investigational Site Number : 2760004
Schönau am Königssee, Germany
Investigational Site Number : 2760003
Wolfsburg, Germany
Investigational Site Number : 3400001
San Pedro Sula, Honduras
Investigational Site Number : 3400002
Tegucigalpa, Honduras
Investigational Site Number : 3400003
Tegucigalpa, Honduras
Investigational Site Number : 6160006
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Investigational Site Number : 6160001
Lodz, Lódzkie, Poland
Investigational Site Number : 6160005
Trzebnica, Lower Silesian Voivodeship, Poland
Investigational Site Number : 6160003
Warsaw, Masovian Voivodeship, Poland
Investigational Site Number : 6160002
Warsaw, Masovian Voivodeship, Poland
Investigational Site Number : 6160004
Siemianowice Śląskie, Silesian Voivodeship, Poland
Investigational Site Number : 7240009
Madrid, Spain
Investigational Site Number : 7240004
Madrid, Spain
Investigational Site Number : 7240007
Seville, Sevilla, Spain
Investigational Site Number : 8260004
Exeter, Devon, United Kingdom
Investigational Site Number : 8260007
London, England, United Kingdom
Investigational Site Number : 8260009
London, England, United Kingdom
Investigational Site Number : 8260010
Southampton, Hampshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.